Video
Dr. Ehdaie encourages further research on focal therapy in prostate cancer
Author(s):
Video Player is loading.
In this video, Behfar Ehdaie, MD, MPH, discusses the takeaways of the study, “MRI-guided focused ultrasound (MRgFUS) focal therapy for intermediate-risk prostate cancer: final results of a phase IIb multicenter study,” presented at the 2021 American Urological Association annual meeting. Ehdaie is an assistant member of the urology service department of surgery at Memorial Sloan Kettering Cancer Center, New York City, New York.
Related Videos
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Related Content
